EMA/413906/2024

European Medicines Agency decision

P/0331/2024

of 13 September 2024

on the acceptance of a modification of an agreed paediatric investigation plan for macimorelin (Ghryvelin), (EMEA-001988-PIP01-16-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0331/2024

of 13 September 2024

on the acceptance of a modification of an agreed paediatric investigation plan for macimorelin (Ghryvelin), (EMEA-001988-PIP01-16-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0105/2017 issued on 11 April 2017 and the decision P/0076/2020 issued on 6 April 2020,

Having regard to the application submitted by Atnahs Pharma Netherlands B. V. on 26 March 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 July 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for macimorelin (Ghryvelin), granules for oral solution, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Atnahs Pharma Netherlands B. V., Copenhagen Towers, Ørestads Boulevard 108, 5.tv, DK-2300 - København S, Denmark.

EMA/PDCO/218981/2024
Amsterdam, 26 July 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001988-PIP01-16-M02

Scope of the application

Active substance(s):

Macimorelin

Invented name and authorisation status:

See Annex II

Condition(s):

Diagnosis of growth hormone deficiency

Pharmaceutical form(s):

Granules for oral solution

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Atnahs Pharma Netherlands B. V.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Atnahs Pharma Netherlands B. V. submitted to the European Medicines Agency on 26 March 2024 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0105/2017 issued on 11 April 2017 and the decision P/0076/2020 issued on 6 April 2020.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral

The procedure started on 27 May 2024.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Diagnosis of growth hormone deficiency

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- granules for oral solution, oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition

Diagnosis of growth hormone deficiency

2.1.1. Indication(s) targeted by the PIP

Diagnosis of growth hormone deficiency

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Granules for oral solution

2.1.4. Measures

Area	**Description**
Quality-related studies	Not applicable.
Non-clinical studies	Not applicable.
Clinical studies	**Study 1** Open label, single dose trial to investigate the pharmacokinetics, pharmcodynamics, safety and tolerability of macimorelin acetate after ascending single oral doses of macimorelin in paediatric patients from 2 to less than 18 years of age with suspected growth hormone deficiency (AEZS-130-P01) **Study 2** Open label, single dose trial to determine the diagnostic efficacy and safety of macimorelin acetate in paediatric patients from 2 to less

	than 18 years of age with suspected growth hormone deficiency (AEZS-130-P02)
Extrapolation, modelling and simulation studies	Not applicable.
Other studies	Not applicable.
Other measures	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2024
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s):

1. Diagnosis of growth hormone deficiency

Authorised indication(s):

- Macimorelin Aeterna Zentaris is indicated for the diagnosis of growth hormone deficiency (GHD) in adults
  - Invented name(s): Ghryvelin (previously Macimorelin Aeterna Zentaris)
  - Authorised pharmaceutical form(s): Granules for oral solution
  - Authorised route(s) of administration: Oral use
  - Authorised via centralised procedure